Jefferies Financial Group Inc. Ironwood Pharmaceuticals Inc Transaction History

Jefferies Financial Group Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$8.32 - $15.45 $1.63 Million - $3.02 Million	-195,331 Reduced 84.17%	36,750 $320,000
Q4 2023 Feb 13, 2024	BUY	$8.79 - $11.51 $187,587 - $245,634	21,341 Added 10.13%	232,081 $2.66 Million
Q3 2023 Nov 14, 2023	SELL	$8.25 - $11.35 $997,911 - $1.37 Million	-120,959 Reduced 36.47%	210,740 $2.03 Million
Q2 2023 Aug 14, 2023	BUY	$10.1 - $11.6 $1.7 Million - $1.95 Million	168,299 Added 103.0%	331,699 $3.53 Million
Q1 2023 May 15, 2023	BUY	$10.37 - $12.56 $1.1 Million - $1.33 Million	106,162 Added 185.47%	163,400 $1.72 Million
Q4 2022 Feb 14, 2023	BUY	$9.9 - $12.43 $566,656 - $711,468	57,238 New	57,238 $709,000

238

162M

11.2M

9.1K

Ticker IRWD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 153,231,008
Market Cap $527M
Description
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZE...

Get notified when there are updates to the investment portfolio of Jefferies Financial Group Inc., based on Form 13F filings with the SEC.

Stay updated on Jefferies Financial Group Inc. with notifications on news.